The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis
Abstract
:1. Introduction
2. Pathophysiological Mechanisms of CFRD
3. Continuous Glucose Monitoring in CFRD Screening
3.1. CGM Screening Studies
3.2. CGM to Predict Future CFRD
3.3. Reproducibility of CGM Measures for Screening
3.4. Shortcomings of the OGTT for Screening
3.5. Advantages and Disadvantages of CGM for Screening
4. Continuous Glucose Monitoring and CF-Specific Clinical Outcomes
5. Early Treatment of CGM-Detected Dysglycemia
6. Future Directions
7. Conclusions
Funding
Conflicts of Interest
References
- O’Sullivan, B.P.; Freedman, S.D. Cystic fibrosis. Lancet 2009, 373, 1891–1904. [Google Scholar] [CrossRef]
- De Boeck, K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020, 109, 893–899. [Google Scholar] [CrossRef] [PubMed]
- Norris, A.W.; Ode, K.L.; Merjaneh, L.; Sanda, S.; Yi, Y.; Sun, X.; Engelhardt, J.F.; Hull, R.L. Survival in a bad neighborhood: Pancreatic islets in cystic fibrosis. J. Endocrinol. 2019, 241, R35–R50. [Google Scholar] [CrossRef] [PubMed]
- Putman, M.S.; Norris, A.W.; Hull, R.L.; Rickels, M.R.; Sussel, L.; Blackman, S.M.; Chan, C.L.; Ode, K.L.; Daley, T.; Stecenko, A.A.; et al. Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes. Diabetes 2023, 72, 677–689. [Google Scholar] [CrossRef] [PubMed]
- Moran, A.; Becker, D.; Casella, S.J.; Gottlieb, P.A.; Kirkman, M.S.; Marshall, B.C.; Slovis, B.; CFRD Consensus Conference Committee. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: A technical review. Diabetes Care 2010, 33, 2677–2683. [Google Scholar] [CrossRef] [PubMed]
- Lurquin, F.; Buysschaert, M.; Preumont, V. Advances in cystic fibrosis-related diabetes: Current status and future directions. Diabetes Metab. Syndr. 2023, 17, 102899. [Google Scholar] [CrossRef] [PubMed]
- Kelsey, R.; Manderson Koivula, F.N.; McClenaghan, N.H.; Kelly, C. Cystic Fibrosis-Related Diabetes: Pathophysiology and Therapeutic Challenges. Clin. Med. Insights Endocrinol. Diabetes 2019, 12, 1179551419851770. [Google Scholar] [CrossRef] [PubMed]
- Gojsina, B.; Minic, P.; Todorovic, S.; Soldatovic, I.; Sovtic, A. Continuous Glucose Monitoring as a Valuable Tool in the Early Detection of Diabetes Related to Cystic Fibrosis. Front. Pediatr. 2021, 9, 659728. [Google Scholar] [CrossRef]
- James, H.A.; O’neill, B.T.; Sreekumaran Nair, K. Insulin Regulation of Proteostasis and Clinical Implications. Cell Metab. 2017, 26, 310–323. [Google Scholar]
- Brennan, A.L.; Gyi, K.M.; Wood, D.M.; Johnson, J.; Holliman, R.; Baines, D.L.; Philips, B.J.; Geddes, D.M.; Hodson, M.E.; Baker, E.H. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J. Cyst. Fibros. 2007, 6, 101–109. [Google Scholar] [CrossRef]
- Kayani, K.; Mohammed, R.; Mohiaddin, H. Cystic Fibrosis-Related Diabetes. Front. Endocrinol. 2018, 9, 20. [Google Scholar] [CrossRef]
- Anton-Păduraru, D.-T.; Murgu, A.M.; Donos, M.A.; Trofin, F.; Azoicăi, A.N.; Popovici, P.; Stana, A.B.; Gheorghiescu, I.; Trandafir, L.M. An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents. Children 2023, 10, 1879. [Google Scholar] [CrossRef] [PubMed]
- Mozzillo, E.; Franceschi, R.; Piona, C.; Passanisi, S.; Casertano, A.; Pjetraj, D.; Maltoni, G.; Calcaterra, V.; Cauvin, V.; Cherubini, V.; et al. Diabetes and Prediabetes in Children with Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED). Front. Endocrinol. 2021, 12, 673539. [Google Scholar] [CrossRef] [PubMed]
- Scheuing, N.; Badenhoop, K.; Borkenstein, M.; Konrad, K.; Lilienthal, E.; Laubner, K.; Naeke, A.; Rami-Merhar, B.; Thon, A.; Wiemann, D.; et al. Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes? Pediatr. Diabetes 2015, 16, 10–15. [Google Scholar] [CrossRef] [PubMed]
- Ode, K.L.; Chan, C.L.; Granados, A.; Moheet, A.; Moran, A.; Brennan, A.L. Cystic fibrosis related diabetes: Medical management. J. Cyst. Fibros. 2019, 18, S10–S18. [Google Scholar] [CrossRef] [PubMed]
- Doan, L.V.; Madison, L.D. Cystic Fibrosis–Related Diabetes. In StatPearls; StatPearls Publishing: Treasure, Island, 2023. [Google Scholar]
- Chamnan, P.; Shine, B.S.F.; Haworth, C.S.; Bilton, D.; Adler, A.I. Diabetes as a Determinant of Mortality in Cystic Fibrosis. Diabetes Care 2010, 33, 311–316. [Google Scholar] [CrossRef]
- Marshall, B.C.; Butler, S.M.; Stoddard, M.; Moran, A.M.; Liou, T.G.; Morgan, W.J. Epidemiology of cystic fibrosis-related diabetes. J. Pediatr. 2005, 146, 681–687. [Google Scholar] [CrossRef] [PubMed]
- Sandouk, Z.; Khan, F.; Khare, S.; Moran, A. Cystic fibrosis related diabetes (CFRD) prognosis. J. Clin. Transl. Endocrinol. 2021, 26, 100278. [Google Scholar] [CrossRef]
- Moran, A.; Brunzell, C.; Cohen, R.C.; Katz, M.; Marshall, B.C.; Onady, G.; Robinson, K.A.; Sabadosa, K.A.; Stecenko, A.; Slovis, B.; et al. Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes. Diabetes Care 2010, 33, 2697–2708. [Google Scholar] [CrossRef]
- Cystic Fibrosis Foundation Patient Registry: Annual. Available online: https://scholar.google.com/scholar_lookup?title=Annual%20data%20report%20bethesda%2C%20Maryland%202022%20cystic%20fibrosis%20foundationle&publication_year=2021&author=Cystic%20Fibrosis%20Foundation%20Patient%20Registry (accessed on 10 March 2021).
- Scully, K.J.; Sherwood, J.S.; Martin, K.; Ruazol, M.; Marchetti, P.; Larkin, M.; Zheng, H.; Sawicki, G.S.; Uluer, A.; Neuringer, I.; et al. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J. Clin. Endocrinol. Metab. 2022, 107, e1444–e1454. [Google Scholar] [CrossRef]
- Dobson, L.; Sheldon, C.D.; Hattersley, A.T. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet. Med. 2004, 21, 691–696. [Google Scholar] [CrossRef]
- Brugha, R.; Wright, M.; Nolan, S.; Bridges, N.; Carr, S.B. Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis. J. Cyst. Fibros. 2017, 17, 791–797. [Google Scholar] [CrossRef] [PubMed]
- Leclercq, A.; Gauthier, B.; Rosner, V.; Weiss, L.; Moreau, F.; Constantinescu, A.A.; Kessler, R.; Kessler, L. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J. Cyst. Fibros. 2014, 13, 478–484. [Google Scholar] [CrossRef]
- O’Riordan, S.M.P.; Hindmarsh, P.; Hill, N.R.; Matthews, D.R.; George, S.; Greally, P.; Canny, G.; Slattery, D.; Murphy, N.; Roche, E.; et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: A prospective cohort study. Diabetes Care 2009, 32, 1020–1022. [Google Scholar] [CrossRef]
- Chan, C.L.; Larson Ode, K.; Granados, A.; Moheet, A.; Moran, A.; Hameed, S. Continuous glucose monitoring in cystic fibrosis À A practical guide. J. Cyst. Fibros. 2019, 18, S25–S31. [Google Scholar] [CrossRef] [PubMed]
- Yapanis, M.; James, S.; Craig, M.E.; O’Neal, D.; Ekinci, E.I. Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring. J. Clin. Endocrinol. Metab. 2022, 107, e2221–e2236. [Google Scholar] [CrossRef]
- Chan, C.L.; Vigers, T.; Pyle, L.; Zeitler, P.S.; Sagel, S.D.; Nadeau, K.J. Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. J. Cyst. Fibros. 2018, 17, 783–790. [Google Scholar] [CrossRef]
- Prentice, B.J.; Ooi, C.Y.; Strachan, R.E.; Hameed, S.; Ebrahimkhani, S.; Waters, S.A.; Verge, C.F.; Widger, J. Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis. J. Cyst. Fibros. 2019, 18, 869–873. [Google Scholar] [CrossRef] [PubMed]
- ElSayed, N.A.; Aleppo, G.; Aroda, V.R.; Bannuru, R.R.; Brown, F.M.; Bruemmer, D.; Collins, B.S.; Gaglia, J.L.; Hilliard, M.E.; Isaacs, D.; et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023, 46, S19–S40. [Google Scholar] [CrossRef]
- Moran, A.; Diem, P.; Klein, D.J.; Levitt, M.D.; Robertson, R.P. Pancreatic endocrine function in cystic fibrosis. J. Pediatr. 1991, 118, 715–723. [Google Scholar] [CrossRef]
- Hardin, D.S.; Grilley, K.; Baron, B.; Hale, K.A. Accelerated Red Blood Cell Turnover Can Invalidate the Use of Hemoglobin A1c as a Diagnostic Test for Cystic Fibrosis Related Diabetes. Pediatr. Res. 1999, 45, 90A. [Google Scholar] [CrossRef]
- Armaghanian, N.; Brand-Miller, J.C.; Markovic, T.P.; Steinbeck, K.S. Hypoglycaemia in cystic fibrosis in the absence of diabetes: A systematic review. J. Cyst. Fibros. 2016, 15, 274–284. [Google Scholar] [CrossRef]
- Zorron, M.; Marson, F.A.L.; Morcillo, A.M.; Gonçalves, A.C.; El Beck, M.S.; Ribeiro, J.D.; Ribeiro, A.F. Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome? J. Bras. Pneumol. 2022, 48, e20210307. [Google Scholar] [CrossRef]
- Granados, A.; Chan, C.L.; Ode, K.L.; Moheet, A.; Moran, A.; Holl, R. Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J. Cyst. Fibros. 2019, 18, S3–S9. [Google Scholar] [CrossRef]
- Coderre, L.; Debieche, L.; Plourde, J.; Rabasa-Lhoret, R.; Lesage, S. The Potential Causes of Cystic Fibrosis-Related Diabetes. Front. Endocrinol. 2021, 12, 702823. [Google Scholar] [CrossRef]
- Castellani, C.; Duff, A.J.; Bell, S.C.; Heijerman, H.G.; Munck, A.; Ratjen, F.; Sermet-Gaudelus, I.; Southern, K.W.; Barben, J.; Flume, P.A.; et al. ECFS best practice guidelines: The 2018 revision. J. Cyst. Fibros. 2018, 17, 153–178. [Google Scholar] [CrossRef]
- Chan, C.L.; Pyle, L.; Vigers, T.; Zeitler, P.S.; Nadeau, K.J. The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults with Cystic Fibrosis. J. Clin. Endocrinol. Metab. 2022, 107, e548–e560. [Google Scholar] [CrossRef]
- Kumar, S.; Pallin, M.; Soldatos, G.; Teede, H. Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review. J. Clin. Transl. Endocrinol. 2022, 30, 100305. [Google Scholar] [CrossRef] [PubMed]
- Adler, A.I.; Shine, B.; Haworth, C.; Leelarathna, L.; Bilton, D. Hyperglycemia and death in cystic fibrosis-related diabetes. Diabetes Care 2011, 34, 1577–1578. [Google Scholar] [CrossRef] [PubMed]
- Taylor-Cousar, J.L.; Janssen, J.S.; Wilson, A.; Clair, C.G.S.; Pickard, K.M.; Jones, M.C.; Brayshaw, S.J.; Chacon, C.S.; Barboa, C.M.; Sontag, M.K.; et al. Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes. J. Diabetes Res. 2016, 2016, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Schiaffini, R.; Brufani, C.; Russo, B.; Fintini, D.; Migliaccio, A.; Pecorelli, L.; Bizzarri, C.; Lucidi, V.; Cappa, M. Abnormal glucose tolerance in children with cystic fibrosis: The predictive role of continuous glucose monitoring system. Eur. J. Endocrinol. 2010, 162, 705–710. [Google Scholar] [CrossRef] [PubMed]
- Rabasa-Lhoret, R.; Kessler, L.; Durieu, I. Identification of Dysglycemia with Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis. ClinicalTrials.gov Identifier: NCT05099939. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT05099939?term=ProspeC-F&draw=2&rank=1 (accessed on 14 January 2024).
- Piona, C.; Volpi, S.; Zusi, C.; Mozzillo, E.; Tosco, A.; Franzese, A.; Raia, V.; Boselli, M.L.; Trombetta, M.; Cipolli, M.; et al. Glucose Tolerance Stages in Cystic Fibrosis Are Identified by a Unique Pattern of Defects of Beta-Cell Function. J. Clin. Endocrinol. Metab. 2021, 106, 1793–1802. [Google Scholar] [CrossRef]
- Kutney, K.; Kaminski, B.A.; Casey, T.; O’riordan, M.; Gubitosi-Klug, R. Reproducibility of in-home CFRD screening using continuous glucose monitoring and mixed meal tolerance test. J. Clin. Transl. Endocrinol. 2023, 33, 100323. [Google Scholar] [CrossRef]
- Balion, C.M.; Raina, P.S.; Gerstein, H.C.; Santaguida, P.L.; Morrison, K.M.; Booker, L.; Hunt, D.L. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: A systematic review. Clin. Chem. Lab. Med. 2007, 45, 1180–1185. [Google Scholar] [CrossRef]
- Prentice, B.J.; Ooi, C.Y.; Verge, C.F.; Hameed, S.; Widger, J. Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis. J. Cyst. Fibros. 2020, 19, 700–703. [Google Scholar] [CrossRef] [PubMed]
- Godbout, A.; Hammana, I.; Potvin, S.; Mainville, D.; Rakel, A.; Berthiaume, Y.; Chiasson, J.-L.; Coderre, L.; Rabasa-Lhoret, R. No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab. 2008, 34, 568–573. [Google Scholar] [CrossRef] [PubMed]
- Izsák, V.D.; Soós, A.; Szakács, Z.; Hegyi, P.; Juhász, M.F.; Varannai, O.; Martonosi, R.; Földi, M.; Kozma, A.; Vajda, Z.; et al. Screening methods for diagnosing cystic fibrosis-related diabetes: A network meta-analysis of diagnostic accuracy studies. Biomolecules 2021, 11, 520. [Google Scholar] [CrossRef] [PubMed]
- Chan, C.L.; Hope, E.; Thurston, J.; Vigers, T.; Pyle, L.; Zeitler, P.S.; Nadeau, K.J. Hemoglobin A1c Accurately Predicts Continuous Glucose Monitoring-Derived Average Glucose in Youth and Young Adults with Cystic Fibrosis. Diabetes Care 2018, 41, 1406–1413. [Google Scholar] [CrossRef]
- Scheuing, N.; Holl, R.W.; Dockter, G.; Hermann, J.M.; Junge, S.; Koerner-Rettberg, C.; Naehrlich, L.; Smaczny, C.; Staab, D.; Thalhammer, G.; et al. High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: A multicenter screening study. PLoS ONE 2014, 9, e112578. [Google Scholar] [CrossRef]
- Brodsky, J.; Dougherty, S.; Makani, R.; Rubenstein, R.C.; Kelly, A. Elevation of 1-Hour Plasma Glucose during Oral Glucose Tolerance Testing Is Associated with Worse Pulmonary Function in Cystic Fibrosis. Diabetes Care 2011, 34, 292–295. [Google Scholar] [CrossRef]
- Prentice, B.J.; Chelliah, A.; Ooi, C.Y.; Hameed, S.; Verge, C.F.; Plush, L.; Widger, J. Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis. J. Cyst. Fibros. 2010, 19, 305–309. [Google Scholar] [CrossRef]
- Elidottir, H.; Diemer, S.; Eklund, E.; Hansen, C.R. Abnormal glucose tolerance and lung function in children with cystic fibrosis. Comparing oral glucose tolerance test and continuous glucose monitoring. J. Cyst. Fibros. 2021, 20, 779–784. [Google Scholar] [CrossRef]
- Frost, F.; Dyce, P.; Nazareth, D.; Malone, V.; Walshaw, M.J. Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes. J. Cyst. Fibros. 2018, 17, 798–803. [Google Scholar] [CrossRef] [PubMed]
- Hameed, S.; Morton, J.R.; Jaffé, A.; Field, P.I.; Belessis, Y.; Yoong, T.; Katz, T.; Verge, C.F. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010, 33, 221–226. [Google Scholar] [CrossRef] [PubMed]
- Declercq, D.; Helleputte, S.; Marchand, S.; Van Aken, S.; Van Braeckel, E.; Van Daele, S.; T’Sjoen, G.; Van Biervliet, S.; Lapauw, B. Glycemic indices at night measured by CGM are predictive for a lower pulmonary function in adults but not in children with cystic fibrosis. J. Cyst. Fibros. 2023, 22, 59–65. [Google Scholar] [CrossRef] [PubMed]
- Hameed, S.; Morton, J.R.; Field, P.I.; Belessis, Y.; Yoong, T.; Katz, T.; Woodhead, H.J.; Walker, J.L.; Neville, K.A.; Campbell, T.A.; et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch. Dis. Child 2012, 97, 464–467. [Google Scholar] [CrossRef]
- Verge, C. Cystic Fibrosis–Insulin Deficiency, Early Action. ClinicalTrials.gov Identifier: NCT01100892. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT01100892 (accessed on 14 January 2024).
First Author Publ. Year | Age Range | Patient Group Size | CGM Duration | CGM Used | CGM Blinded | Glycemic Categories at Baseline | CGM Measures Examined | Cut-Off Value/Findings |
---|---|---|---|---|---|---|---|---|
Chan et al., 2022 [39] | 6–25 | 85 | 3–7 days | Medtronic, Minimed | Yes | NGT n = 27 AGT n = 45 CFRD n = 13 |
|
|
Scully et al., 2022 [22] | 8–70 | 77 | 25.5 ± 9 days | Free Style Libre | Yes | NGT n = 24 AGT n = 22 CFRD n = 31 |
|
|
First Author, Publ. Year, and Ref. No. | Age Range | Patient Group Size | CGM Duration | CGM Used | CGM Blinded | Cut-Off Value/Findings |
---|---|---|---|---|---|---|
Hameed et al., 2010 [57] | 10–18 | 25 | 5 days | Medronic | No |
|
Zorron et al., 2022 [35] | 10–19 | 39 | 3 days | Medtronic MiniMed | Yes |
|
Elidottir et al., 2021 [55] | 7–16 | 32 | 14 days | Freestyle Libre | No |
|
Leclercq et al., 2013 [25] | 12–57 | 38 | NR | Medronic | No |
|
Taylor-Cousar 2016 [42] | 20–65 | 18 | 3 days | Medronic |
| |
Declercq et al., 2023 [58] | 9–43 | 47 | 7 days | DexcomG4 | Yes |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kirigin Biloš, L.S.; Altabas, V.; Vukić Dugac, A.; Baretić, M. The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis. Medicina 2024, 60, 477. https://doi.org/10.3390/medicina60030477
Kirigin Biloš LS, Altabas V, Vukić Dugac A, Baretić M. The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis. Medicina. 2024; 60(3):477. https://doi.org/10.3390/medicina60030477
Chicago/Turabian StyleKirigin Biloš, Lora Stanka, Velimir Altabas, Andrea Vukić Dugac, and Maja Baretić. 2024. "The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis" Medicina 60, no. 3: 477. https://doi.org/10.3390/medicina60030477